Mock analytics · Last 30 days

Hemophilia community intelligence

De-identified assistant analytics for advocacy leaders, chapter teams, medical reviewers, and treatment partners. All figures below are synthetic but modeled on realistic patient-support and education workflows.

Live assistant signal 4,862 sessions analyzed from WFHUSA and NBDF demo experiences
Chat sessions 4,862 +18.4% vs prior 30 days
Questions asked 12,740 2.6 per session
Answered with citations 87.4% +5.1 pts after doc refresh
Unsupported questions 994 7.8% need content review
Care routing flags 64 14 same-day handoffs

Demand signal

Top question themes

12,740 total questions
Treatment options and switching
24%
Insurance, copay, and access
18%
Managing acute bleeds
14%
Gene therapy eligibility
11%
Women, girls, and VWD
10%
Inhibitors and complex care
8%
School, travel, and sports
7%
Trials and research participation
5%

Audience

Patient journey segments

Newly diagnosed families 1,126 sessions · highest need for basics and emergency plans
Treatment switchers 842 sessions · comparing factor, non-factor, and dosing burden
Adult women with VWD 611 sessions · iron deficiency, menstruation, pregnancy planning
Gene therapy evaluators 388 sessions · durability, liver monitoring, eligibility

Evidence usage

Most referenced documents

1,006 cited answers
MASAC emergency management guidance Bleed action plans, ED letters, head injury questions
214 refs
NBDF Treatment Options Guide Comparisons across prophylaxis, on-demand, and adjunctive care
187 refs
WFH Guidelines for Hemophilia, 3rd edition Global standard-of-care and inhibitor-management questions
156 refs
HEMLIBRA prescribing information Dosing, breakthrough bleed guidance, lab-test caveats
119 refs
Gene therapy shared decision aid Eligibility, liver monitoring, post-infusion expectations
92 refs

Content gaps

Unsupported or low-confidence questions

994 questions
Switching from emicizumab to extended half-life FVIII 142 asks · create neutral switching FAQ with HCP review.
Travel after gene therapy infusion 88 asks · missing patient-friendly monitoring checklist.
Tranexamic acid, VWD, and pregnancy planning 74 asks · needs women's health resource expansion.
Appealing payer denial for newer prophylaxis 69 asks · opportunity for access-support template.
Sports return-to-play after joint bleed 63 asks · no current plain-language rehab guidance.

Treatment intelligence

Medication and class mentions

2,184 treatment mentions
Treatment Mentions Common intent
HEMLIBRA / emicizumab 426 breakthrough bleeds, lab tests, switching
ALTUVIIIO / efanesoctocog alfa 238 weekly dosing, activity coverage, access
Gene therapy: ROCTAVIAN, BEQVEZ 214 eligibility, durability, liver monitoring
Extended half-life FIX products 172 dosing intervals, travel, sports coverage
Desmopressin and tranexamic acid 149 VWD, dental work, heavy menstrual bleeding
HYMPAVZI / marstacimab 97 new approval questions, eligibility, side effects

Care coordination

Patient support routing signals

Care review

These are topics raised in chat that may warrant follow-up with a care team or medical information — not medical assessments or confirmed clinical findings.

18 breakthrough bleeding after missed or delayed prophylaxis
12 injection-site reactions or injection anxiety
9 headache, fatigue, or elevated liver enzyme concerns after gene therapy
7 thrombosis-related concerns with product combinations
6 suspected inhibitor recurrence or treatment no longer working

Partner opportunity

Access and affordability

18% of questions mention coverage, prior authorization, copay cards, Medicaid renewal, or accumulator concerns. Highest growth is among caregivers of children considering a prophylaxis switch.

Build payer appeal templates

Partner opportunity

Neutral treatment comparison

Patients ask for side-by-side language comparing dosing, monitoring, bleed protection, contraindications, and lifestyle fit across factor, non-factor, and gene therapy options.

Create HCP-reviewed comparison guide

Partner opportunity

Medical information handoff

312 sessions show intent to ask product-specific clinical, switching, or dosing questions that should be routed to sponsor medical information or a care team.

Add sponsor-specific care handoff workflows

Voice of community

Anonymized question samples

Representative, synthetic excerpts

"My son had a knee bleed after basketball even though he is on weekly prophylaxis. What should I ask our HTC before changing products?"

Caregiver · cited emergency management and treatment guide

"I keep hearing about gene therapy. How long do the benefits last, and what happens if my factor level drops later?"

Adult with hemophilia B · cited gene therapy decision aid

"Are heavy periods and low iron connected to VWD, and what documents can I bring to my OB-GYN?"

Adult woman with VWD · content gap flagged